Osaka University partner with Takara Bio for new genome medicine
Osaka University and Takara Bio Inc. announced on August 8 a new initiative for genome medicine. According to the agreement, a clinical sequencing lab will be established at Osaka University that uses next generation sequencers for new cancer diagnostics.
Based on this program, researchers aim to create new genome medicine for diagnosis and treatment (personalized medicine) along with the selection of effective drugs. Genome medicine is especially expected to have an impact in cancer therapy by both improving patient outcomes and lowering patient burden.
Osaka University Hospital and the Graduate School of Medicine are conducting genome medicine research and building the necessary facilities. They are also establishing a genomic counseling service for patients. Takara Bio established Japan’s first large-scale genome analysis facility in 2000.
The Clinical Sequence Lab being developed through this collaboration will follow international guidelines for quality management that are in accordance with CAP-LAP and CLIA (Clinical Laboratory Improvement Amendments). The laboratory is expected to become a basis for clinical genome medicine research and education in Japan.
Genome Medicine: Uses information from the patient’s genome to develop treatment strategies.
Use of genetic analysis in drug development and other treatments. Clinical sequencing has gained traction in cancer research.
Next generation sequencer
Technology for high throughput analysis of DNA and RNA sequences.
CAP = College of American Pathologists
LAP = Laboratory Accreditation Program
CAP-LAP is an accreditation program for laboratory testing recognized internationally.
CLIA Clinical Laboratory Improvement Amendments describes U.S. standards for sites that use human specimens to diagnose, prevent or treat disease.